Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Comparison of TERT and 5-Hydroxymethylcytocine immunohistochemistry in various thyroid carcinomas.

Annals of diagnostic pathology - 1 Aug 2024

An Hyeong Rok, Kim Won Gu, Lee Yu-Mi, Sung Tae-Yon, Song Dong Eun

Abstract excerpt

Telomerase reverse transcriptase (TERT) promoter mutation is associated with an aggressive clinical course in thyroid carcinomas. Therefore, detection of TERT promoter mutation is essential for proper patient management. 5-Hydroxymethylcytosine (5hmC) is an epigenetic marker involved in the DNA demethylation pathway, and its loss has been observed in various tumors. Loss of 5hmC has also been reported in thyroid...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to 5-Methylcytosine
Share to Aged
Share to Biomarkers, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immunohistochemistry

Share to Promoter Regions, Genetic

Share to Sensitivity and Specificity

Share to Telomerase

Share to Thyroid Neoplasms

Source

Identifiers

PMID: 38552304
DOI: 10.1016/j.anndiagpath.2024.152290

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 11 closest

Comparison of TERT and 5-Hydroxymethylcytocine immunohistochemistry in various thyroid carcinomas.PMID 38552304Read ↗

Loss of 5-Hydroxymethylcytosine is an Epigenetic Hallmark of Thyroid Carcinomas with TERT Promoter Mutations.Semantic proximity Read ↗

The role of 5-hydroxymethylcytosine as a potential epigenetic biomarker in a large series of thyroid neoplasmSemantic proximity Read ↗

5hmC Immunohistochemistry: A Predictor of TERT Promoter Mutational Status in Follicular Thyroid Carcinoma?Semantic proximity Read ↗

TERT promoter methylation is associated with high expression of TERT and poor prognosis in papillary thyroid cancerSemantic proximity Read ↗

Clinicopathological indicators for TERT promoter mutation in papillary thyroid carcinoma.Semantic proximity Read ↗

TERT mRNA Expression as a Novel Prognostic Marker in Papillary Thyroid CarcinomasSemantic proximity Read ↗

TERT upstream promoter methylation regulates TERT expression and acts as a therapeutic target in TERT promoter mutation-negative thyroid cancerSemantic proximity Read ↗

Global 5-Hydroxymethylcytosine Levels Are Profoundly Reduced in Multiple Genitourinary MalignanciesSemantic proximity Read ↗

TERT aberrancies: a screening tool for malignancy in follicular thyroid tumoursSemantic proximity Read ↗

In Japanese patients with papillary thyroid carcinoma, TERT promoter mutation is associated with poor prognosis, in contrast to BRAF V600E mutation.Semantic proximity Read ↗

Loss of 5-hydroxymethylcytosine is accompanied with malignant cellular transformation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.